These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33046401)

  • 21. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
    Thiruvenkatarajan V; Meyer EJ; Nanjappa N; Van Wijk RM; Jesudason D
    Br J Anaesth; 2019 Jul; 123(1):27-36. PubMed ID: 31060732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
    Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
    Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.
    Ata F; Yousaf Z; Khan AA; Razok A; Akram J; Ali EAH; Abdalhadi A; Ibrahim DA; Al Mohanadi DHSH; Danjuma MI
    Sci Rep; 2021 May; 11(1):10293. PubMed ID: 33986421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Population-Based Study of SGLT2 Inhibitor-Associated Postoperative Diabetic Ketoacidosis in Patients with Type 2 Diabetes.
    Lui DTW; Wu T; Au ICH; Liu X; Fung MMH; Lee CH; Fong CHY; Woo YC; Lang BHH; Tan KCB; Wong CKH
    Drug Saf; 2023 Jan; 46(1):53-64. PubMed ID: 36289137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management.
    McCann M; O'Brien A; Larbalestier R; Davis T
    Intern Med J; 2022 May; 52(5):876-879. PubMed ID: 35538006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sodium-glucose-cotransporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis].
    Fisker F; Møller N; Lauritzen ES
    Ugeskr Laeger; 2019 May; 181(21):. PubMed ID: 31124439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
    Kitahara C; Morita S; Kishimoto S; Matsuno S; Uraki S; Takeshima K; Furukawa Y; Inaba H; Iwakura H; Ariyasu H; Furuta H; Nishi M; Akamizu T
    J Diabetes Investig; 2021 Apr; 12(4):664-667. PubMed ID: 32686282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series.
    Puls HA; Haas NL; Franklin BJ; Theyyunni N; Harvey CE
    Am J Emerg Med; 2021 Jun; 44():11-13. PubMed ID: 33571749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [SGLT 2 inhibitors in Type 1 diabetes].
    Stougaard EB; Amadid H; Søndergaard E; Jørgensen ME; Persson F; Rossing P
    Ugeskr Laeger; 2020 Aug; 182(35):. PubMed ID: 32829747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Rao L; Ren C; Luo S; Huang C; Li X
    Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.
    Fralick M; Redelmeier DA; Patorno E; Franklin JM; Razak F; Gomes T; Schneeweiss S
    J Gen Intern Med; 2021 Sep; 36(9):2601-2607. PubMed ID: 33564942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.
    Fu EL; D'Andrea E; Wexler DJ; Patorno E; Paik JM
    Clin J Am Soc Nephrol; 2023 May; 18(5):592-601. PubMed ID: 36827225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study.
    Zhao Q; Tan Y; Wu Q; Xiao X; Wei X; Nian M; Yao J; Fan N; Wang R; Fan G
    Expert Opin Drug Saf; 2024 Jan; 23(1):57-65. PubMed ID: 37947121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-Glucose Co-transporter-2 Inhibitors Induced Diabetic Ketoacidosis in Patients Undergoing Bariatric Surgery: a Systematic Review of Case Reports and Case Series.
    Gokhare Viswanath N; Sharma M; Bandlamudi N; Idris I; Singhal R; Mahawar K; Madhok B
    Obes Surg; 2023 Jan; 33(1):339-344. PubMed ID: 36418772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials.
    Zhou Y; Wang FR; Wen FF; Li C; Ye TT
    Acta Cardiol; 2024 May; 79(3):274-283. PubMed ID: 37642395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
    Kamoshima H; Nomoto H; Yamashita K; Takahashi Y; Tsuchida K; Kuwabara S; Miya A; Cho KY; Kameda H; Nakamura A; Atsumi T; Taneda S; Kurihara Y; Aoki S; Ono Y; Miyoshi H
    Endocr J; 2022 May; 69(5):495-509. PubMed ID: 34819409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.